*Only time points with ≥3 observations are plotted. Steady-state mean trough is calculated from all observations at any time point. The mean dose for patients receiving prophylaxis every 7 days was 37 IU/kg and every 14 days was 73 IU/kg.VIEW PEDIATRIC DATA
“It’s the peace of mind I get having high factor levels; especially in my day-to-day life.”Watch John’s full story
*The mean dose for pediatric patients receiving prophylaxis every 7 days was 47 IU/kg.
IDELVION is the only extended half‑life Factor IX therapy to deliver a zero median annualized spontaneous bleeding rate when dosed at 7 or 14 days in clinical trialsVIEW EFFICACY DATA
IDELVION uses albumin fusion technology to extend half‑life with minimal risk of an immune responseSEE THE IDELVION MOA
References: 1. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735. 2. Data on file. Available from CSL Behring as DOF IDL-003. 3. Data on file. Available from CSL Behring as DOF IDL-001.